AvenCell Therapeutics
Germany - DresdenBiotechnology
Focus: AvenCell Therapeutics is a German biotech company developing next-generation CAR-T and T cell-engaging bispecific antibodies for hematologic malignancies and solid tumors. The company is early-stage with 6 programs in Phase 1 and 1 in Phase 1/2, positioning itself in the competitive cell therapy space.
Profile data last refreshed 15h ago · AI intelligence enriched 2w ago
Open Jobs
0
About AvenCell Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow AvenCell Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
9 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Cyclophosphamide
Acute Myeloid Leukemia (AML)Clinical Trials (1)
NCT04230265Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies
Phase 1Help build intelligence for AvenCell Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.